儿茶酚胺敏感性室性心动过速的药物治疗现状  

Status of Drug Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia

作　　者：王婷 樊晓寒 WANG Ting;FAN Xiao-han(Zhengzhou University People's Hopsital,Zhengzhou 450003,China)

机构地区：[1]郑州大学人民医院,郑州市450003

出　　处：《中国分子心脏病学杂志》2021年第2期3906-3910,共5页Molecular Cardiology of China

摘　　要：儿茶酚胺敏感性室性心动过速(CPVT)是一种遗传性离子通道病,其发病年龄小、致死率高,目前的治疗手段主要有药物治疗、植入式心律转复除颤器(ICD)、左心交感神经切除术(LCSD)、导管消融。作为其他治疗手段的基础,本文对现有报道中CPVT患者的药物治疗进行了总结。在药物治疗中,β受体阻滞剂的应用最为广泛,但单药治疗往往效果不佳,其副作用更是增加了患者的不依从性,因此临床上更多的是在β受体阻滞剂的基础上联合其他药物,其中应用最广泛的是β受体阻滞剂联合氟卡尼。值得注意的是,足量给药是药物治疗效果的保障。Catecholaminergic polymorphic ventricular tachycardia(CPVT)is a hereditary ion channel disease with a low onset age and high fatality rate.The current treatment methods mainly include drug therapy,implantable cardioverter defibrillator(ICD),left cardiac sympathetic denervation(LCSD)and catheter ablation.As a basis for other treatments,in this paper,we summarized the current reports on drug therapy for CPVT patients.Beta-blockers are the most widely used drug therapy,but single drug therapy is often ineffective,and the side effects of which increase the patient’s non-adherence,so the clinical choice is more on the basis of beta-blockers combined with other drugs,among which the most widely used is the combination of beta-blockers and flecainide.It is worth noting that sufficient dosage is the guarantee of the effect of drug treatment.

关 键 词：儿茶酚胺敏感性多形性室性心动过速 药物治疗 单药治疗 联合治疗 预期药物 

分 类 号：R541.71[医药卫生—心血管疾病]